EHA-ESMO clinical practice recommendations for PCNSL

The European Hematology Association (EHA) – European Society for Medical Oncology (ESMO) clinical practice guidelines for primary central nervous system lymphoma (PCNSL) provide comprehensive recommendations for managing this condition.¹ The recommendations cover diagnosis, staging and risk assessment, treatment, and follow-up, and were recently published in Annals of Oncology by Ferreri et al.¹

Diagnosis: The guidelines emphasize prompt and accurate clinical diagnosis through biopsy, imaging, and pathological evaluations.

Staging and risk assessment: Detailed protocols for assessing the extent and severity of the disease are provided.

Treatment: Algorithms for the selection of first-line and salvage treatments are included in the recommendations. High-dose methotrexate remains the standard of care; however, newer treatments are being integrated. Patients should be enrolled in a suitable clinical trial whenever possible.

Follow-up: Due to longer survival times for patients with PCNSL, follow-up strategies and monitoring of long-term treatment effects are discussed.

These guidelines aim to improve the management of patients with PCNSL, providing a framework for clinicians to make informed decisions and ultimately improve patient outcomes.